NHS Cancer Blood Test Trial Fails Main Goal.

A large NHS-led clinical trial of a multi-cancer blood test has failed to meet its main objective, according to results presented at a major oncology conference in Chicago. The study evaluated the Galleri test, designed to detect more than 50 types of cancer through a single blood sample.

The trial involved 142,942 participants in the United Kingdom aged between 50 and 77 who showed no symptoms of cancer at the start of the study. Participants were randomly assigned to either receive annual Galleri blood testing in addition to standard NHS screening, or to receive standard screening alone.

Over a three-year period, researchers aimed to determine whether the test could shift cancer detection toward earlier, more treatable stages. The primary endpoint of the study was to reduce the number of stage three and stage four cancer diagnoses among those who received the test.

However, results showed no statistically significant reduction in late-stage cancer diagnoses compared with the control group. This means the test did not achieve its key goal of improving early detection outcomes at a measurable level.

Experts presenting the findings at the American Society of Clinical Oncology (ASCO) annual meeting described mixed results. ASCO’s chief medical officer, Dr Julie Gralow, noted that while there were some encouraging signs of tumour downstaging, the primary endpoint was not met.

Some researchers and attendees at the conference were more direct in their assessment, suggesting that the trial did not deliver the expected breakthrough in early cancer detection.

The Galleri test remains one of the most widely discussed innovations in oncology due to its potential to detect multiple cancers from a single blood sample. However, this landmark study highlights the challenges of translating early promise into proven clinical benefit at scale.

Further analysis of the trial data is expected, and researchers continue to explore whether refinements to the technology or its application could improve future outcomes in cancer screening.